Source comparison
Hexarelin vs Ipamorelin — Which GH Secretagogue Wins?
Without ghrelin receptor activity data, comparing hexarelin vs ipamorelin becomes a guessing game about which peptide 'feels stronger'. But the mechanism separating these compounds is quantifiable and documented. Hexarelin binds to both growth hormone secretag
This comparison does not assign a generated winner or score.
- Without ghrelin receptor activity data, comparing hexarelin vs ipamorelin becomes a guessing game about which peptide 'feels stronger'. But the mechanism separating these compounds is quantifiable and documented. Hexarelin binds to both growth hormone secretagogue receptor 1a (GHS-R1a) and CD36 scavenger receptors, triggering immediate, high-amplitude GH release alongside cortisol and prolactin elevation. Ipamorelin selectively targets GHS-R1a without secondary receptor activation, producing lower-amplitude GH pulses but zero cortisol spillover and sustained receptor sensitivity across months of use. The GHRF-6 analog family (hexarelin included) desensitizes pituitary somatotrophs within 12–16 weeks of continuous dosing; ipamorelin does not.
- Our team has guided researchers through peptide selection for multi-month protocols since founding Real Peptides in 2018. The gap between choosing hexarelin and choosing ipamorelin comes down to three variables most comparison charts ignore: receptor desensitization timelines, secondary hormone activation, and downstream metabolic signaling beyond GH itself.
- What separates hexarelin from ipamorelin in research applications?
- Hexarelin produces 6–10× baseline growth hormone release within 15 minutes of subcutaneous administration but desensitizes GHS-R1a receptors after 12–16 weeks of daily use. Ipamorelin generates 2–4× baseline GH elevation with identical dosing but maintains receptor sensitivity indefinitely, making it the preferred secretagogue for protocols extending beyond four months. The trade-off: hexarelin's CD36 receptor activation triggers cardioprotective signaling that ipamorelin does not replicate.
- Here's what that means in practice: hexarelin is the compound you choose when peak GH amplitude matters more than sustainability. Ipamorelin is what you choose when the protocol runs six months or longer and you cannot afford receptor downregulation halfway through. The comparison isn't about which peptide is 'better'. It's about which mechanism aligns with your experimental timeline and receptor activity tolerance.
- This article covers the structural differences driving their receptor binding profiles, the desensitization mechanism that limits hexarelin's window, the cortisol and prolactin implications researchers overlook, the dosing protocols that maximize each compound's utility, and the scenarios where one peptide clearly outperforms the other. We've also included quantitative receptor affinity data, half-life comparisons, and the honest assessment most suppliers won't provide about long-term hexarelin use.